Answers are grounded in this paper and cite their sources.
Accurate identification of malignant tumors by magnetic resonance imaging (MRI) remains a critical challenge, as the current clinical contrast agents lack sufficient sensitivity and specificity. Herein, a tumor microenvironment (TME)‐triggered synergistically enhanced T 1 ‐weighted imaging ( T 1 WI) and susceptibility‐weighted imaging (SWI) strategy has been developed using NaGdF 4 nanoprobes. The nanoprobe is strategically designed with a glutathione (GSH)‐cleavable disulfide bond (─S─S─) as the key responsive moiety, together with an RGD peptide sequence and a stealth self‐peptide sequence for active tumor vascular targeting and prolonged blood circulation, respectively. When the nanoprobes are exposed to the abnormally high GSH level in the TME, the cleavage of ─S─S─ induces crosslinking with unreacted maleimide groups on nanoprobes surface, inducing aggregation and magnetic coupling of nanoprobes. This aggregation mainly prolongs rotational correlation time ( τ R ) to enhance T 1 signals, while simultaneously amplifying local magnetic field inhomogeneity resulting in strengthened SWI signals. The activatable nanoprobes exhibit significantly amplified T 1 /SWI dual‐modality signals compared with non‐responsive controls on 4T1 tumor‐bearing mouse models. This study demonstrates that TME‐triggered enhancement of dual‐modality MRI signals overcomes the insufficient tumor contrast and the inherent relaxivity trade‐offs of conventional agents, offering a robust strategy for designing next‐generation activatable nanoprobes for accurate tumor MRI.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: